Navigation Links
Transition Therapeutics Announces Executive Management Appointments
Date:7/3/2008

TORONTO, July 3 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH; NASDAQ: TTHI) Chairman and Chief Executive Officer, Dr. Tony Cruz, is pleased to announce that Mr. Elie Farah has been appointed President in addition to continuing to serve as Chief Financial Officer, and Ms. Nicole Rusaw-George has been appointed to the position of Vice-President, Finance.

"These promotions reflect the strength of our management team and Mr. Farah's and Ms. Rusaw-George's expanding responsibilities in the growth of the Company," commented Dr. Cruz.

Since joining Transition in 2005 as Chief Financial Officer and Vice-President, Corporate Development, Mr. Farah has demonstrated leadership in the execution of the Company's strategic plan across all aspects of the business. Also joining Transition in 2005, Ms. Rusaw-George has held the position of Director of Finance with a focus in the areas of financial reporting and regulatory compliance.

About Transition

----------------

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND005 (AZD-103) for the treatment of Alzheimer's disease and TT-223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally or developed internally using its proprietary drug discovery engine. Transition's shares are listed on the NASDAQ under the symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For additional information about the Company, please visit http://www.transitiontherapeutics.com.

Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release and may be superseded by more recent information we have disclosed in later press releases, filings with the OSC, SEC or otherwise. Except for historical information, this press release may contain forward-looking statements, relating to expectations, plans or prospects for Transition, including conducting clinical trials. These statements are based upon the current expectations and beliefs of Transition's management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include factors beyond Transition's control and the risk factors and other cautionary statements discussed in Transition's quarterly and annual filings with the Canadian commissions.


'/>"/>
SOURCE Transition Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
2. Transition Therapeutics Receives Remaining Upfront Payment from Elan Corporation, plc
3. Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2008 Financial Results on Wednesday, November 14, at 8:30 A.M. EST
4. New UIC center to study end-of-life transition
5. Seabrook House Opens Transitional Living Facility: Seabrook West
6. Transition Therapeutics Announces Milestone Payment from Elan
7. Transition Therapeutics Announces Appointment of Vice-President of Business Development
8. Pure Weight Loss Takes Additional Steps To Assure Seamless Transition For Clients
9. Zimmer Spine Introduces New Rigid to Dynamic Stabilization Transition System
10. Bisexuality not a transitional phase among women, according to new research
11. Transition of Behavioral Health Services from WPIC-BV to Heritage Valley Health System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... Drs. Justin Kolnick, Kara Diamond, ... teaching their patients about the key role this treatment plays in protecting oral health, ... endodontist. To better serve those who need a root canal in White Plains, NY ...
(Date:3/27/2017)... ... March 27, 2017 , ... Buzzies parent company, The TouchPoint ... Rent the Runway Foundation and UBS’ Project Entrepreneur. Mayo will present her pitch about ... , Project Entrepreneur’s second annual venture competition ignites bold ideas by providing women ...
(Date:3/27/2017)... ... March 27, 2017 , ... Osteitis pubis ... type of groin injury, it occurs when the muscles around the pelvis become ... and around the lower torso, as well as accompanying tenderness and weakness. Without ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... of nurses and supply chain professionals, will hold their first Northeast Regional AHVAP ... in Bundles.” , “Increasingly, supply chain and value analysis professionals have a ...
(Date:3/27/2017)... ... March 27, 2017 , ... Mt. Angel Vitamins, a ... months-long rebranding effort. This includes the introduction of new packaging and messaging, as ... research, we learned that a simple, proactive approach to wellness is important to ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 27, 2017 LightIntegra Technology Inc. today announced ... Dubiel as President and Chief Executive Officer effective March ... Board of Directors of LightIntegra. Paul Geyer ... LightIntegra. "This is the perfect time ... Executive Officer. We,ve selected a very strong leader at ...
(Date:3/27/2017)... 27, 2017  Sophiris Bio Inc. (NASDAQ: ... clinical late-stage biopharmaceutical company developing topsalysin (PRX302) for ... reported fourth quarter and full year 2016 financial ... Key Corporate Highlights: Advanced Topsalysin ... During 2016, the Company reported successful results with ...
(Date:3/27/2017)... Pulmatrix, Inc . (NASDAQ: PULM), a clinical stage biopharmaceutical company ... announced that it has added two experts in the fields ... Scientific Advisory Board . The two experts ... MD, former chief of the Pediatric Pulmonary and Allergy Divisions ... University, and David Denning , MD, ...
Breaking Medicine Technology: